Abstract
Drug delivery technologies have been applied to existing anticancer drugs for greater efficacy and favorable safety profiles compared with existing formulations.
LHRH analog and liposomal doxorubicin are incorporated into standard cancer chemotherapy. Albumin bound paclitaxel nanoparticle has been developed to reduce the potential disadvantage of existing formulation for patients and clinical facilities. In this article physicochemical and clinical features of these drug formulations are discussed.
